SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma — Andrew X. Zhu (2014) | RDL Network
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Journal of Clinical Oncology 33(6): 559-566
Article 2014 English
Authors
AZ
Andrew X. Zhu
OR
Olivier Rosmorduc
TE
T.R. Jeffry Evans
Abstract
1 min read
To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial.
Josep M. Llovet, Serafino Ricci, Vincenzo Mazzaferro, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Melanie Poulin-Costello, M. Moscovici, D. Voliotis, Jordi Bruix
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.